Trial reportAmerican journal of respiratory and critical care medicine2020
Thrombomodulin Alfa for Acute Exacerbation of Idiopathic Pulmonary Fibrosis. A Randomized, Double-Blind Placebo-controlled Trial.
Registry-linked trialAbstract readComparative StudyRandomized Controlled Trial
In one paragraph
Trial report in American journal of respiratory and critical care medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05674994 (Glucocorticoids Versus Placebo for the Treatment of Acute Exacerbation of Idiopathic Pulmonary Fibrosis), which is not on this map. Cited by 44 papers, 3 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
44citing papers in PubMed, 3 pooled it
6.8field-weighted citation impact, top 2% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Glucocorticoids Versus Placebo for the Treatment of Acute Exacerbation of Idiopathic Pulmonary Fibrosis: a Randomized Controlled Trial
Who cites it
44 citing papers in PubMed, 3 syntheses or guidelines pooled it, 77 citations in OpenAlex.
- Outcomes of patients with acute exacerbations of idiopathic pulmonary fibrosis treated with corticosteroids: a systematic review and meta-analysis.Respiratory research · 2026Pooled it
- Efficacy and Safety of Anticoagulants in Patients With Idiopathic Pulmonary Fibrosis: A Meta-Analysis.Canadian respiratory journal · 2025Pooled it
- Clinical efficacy and safety of anticoagulants in the treatment of idiopathic pulmonary fibrosis: a systematic review and meta-analysis.Therapeutic advances in respiratory diseasePooled it
- Acute exacerbation in fibrotic interstitial lung disease: an international working group report.American journal of respiratory and critical care medicine · 2026Review
- Acute Exacerbation of Interstitial Lung Disease: A Case Series and a Narrative Literature Review.Advances in respiratory medicine · 2026Review
- A biomarker-guided framework for corticosteroid treatment stratification in acute exacerbation of idiopathic pulmonary fibrosis.Frontiers in pharmacology · 2026Article
- Intravenous Immunoglobulin in Acute Exacerbations of Fibrotic Interstitial Lung Diseases: A Retrospective, Real-World Study.Medicina (Kaunas, Lithuania) · 2025Observational
- Idiopathic Pulmonary Fibrosis, Today and Tomorrow: Certainties and New Therapeutic Horizons.Pulmonary therapy · 2025Review
- Polymyxin B-hemoperfusion in patients with acute exacerbation of idiopathic pulmonary fibrosis: a single-center prospective pilot study.The Korean journal of internal medicine · 2025Article
- The Multifaceted Roles of Thrombomodulin: Anti-coagulation, Anti-inflammation, and Anti-tumor Potential.Current pharmaceutical design · 2025Review
- Baricitinib for Acute Exacerbation in Idiopathic Interstitial Pneumonias: A Preliminary Study Using Propensity Score Matching.Respiration; international review of thoracic diseases · 2025Article
- Clinicopathologic and proteomic characteristics of low-grade undifferentiated spindle cell sarcoma.Frontiers in molecular biosciences · 2025Article
- Treatment of acute exacerbations of interstitial lung diseases with corticosteroids: Evidence?Respirology (Carlton, Vic.) · 2024Article
- Acute exacerbation of idiopathic pulmonary fibrosis a narrative review primary focus on treatments.Journal of thoracic disease · 2024Review
- Design of the STRIVE-IPF trial- study of therapeutic plasma exchange, rituximab, and intravenous immunoglobulin for acute exacerbations of idiopathic pulmonary fibrosis.BMC pulmonary medicine · 2024Article
- Mechanical ventilation in patients with idiopathic pulmonary fibrosis in Korea: a nationwide cohort study.The Korean journal of internal medicine · 2024Observational
- Article
- Design of the STRIVE-IPF Trial- Study of Therapeutic Plasma Exchange, Rituximab, and Intravenous Immunoglobulin for Acute Exacerbations of Idiopathic Pulmonary Fibrosis.Research square · 2024Article
- Article
- Neutrophil-to-Lymphocyte Ratio in Acute Exacerbation of Idiopathic Pulmonary Fibrosis.Journal of clinical medicine · 2023Article
Corrections and comments
- Commented on by
- Commented on by
- Commented on by
- Commented on by
- Commented on by
Authors and funding
36 authors at 20 institutions in 1 country.
Yasuhiro KondohDepartment of Respiratory Medicine and Allergy, Tosei General Hospital, Aichi, Japan.
Arata AzumaDepartment of Pulmonary Medicine and Oncology, Graduate School of Medicine, Nippon Medical School, Tokyo, Japan.
Yoshikazu InoueClincal Research Center, National Hospital Organization Kinki-Chuo Chest Medical Center, Osaka, Japan.
Takashi OguraDivision of Respiratory Medicine, Kanagawa Cardiovascular and Respiratory Center, Kanagawa, Japan.
Susumu SakamotoDepartment of Respiratory Medicine, Toho University Omori Medical Center, Tokyo, Japan.
Kenji TsushimaDepartment of Pulmonary Medicine, School of Medicine, International University of Health and Welfare, Chiba, Japan.
Takeshi JohkohDepartment of Radiology, Kansai Rosai Hospital, Hyogo, Japan.
Kiminori FujimotoDepartment of Radiology and.
Kazuya IchikadoDivision of Respiratory Medicine, Saiseikai Kumamoto Hospital, Kumamoto, Japan.
Yasuo MatsuzawaDepartment of Respiratory Medicine, Toho University Medical Center-Sakura Hospital, Chiba, Japan.
Takefumi SaitoDepartment of Respiratory Medicine, National Hospital Organization, Ibarakihigashi National Hospital, Ibaraki, Japan.
Kazuma KishiDepartment of Respiratory Medicine, Toho University Omori Medical Center, Tokyo, Japan.
Keisuke TomiiDepartment of Respiratory Medicine, Kobe City Medical Center General Hospital, Hyogo, Japan.
Noriho SakamotoDepartment of Respiratory Medicine, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan.
Masahiro AoshimaDepartment of Pulmonology, Kameda Medical Center, Chiba, Japan.
Jun ArayaDivision of Respiratory Diseases, Department of Internal Medicine, Jikei University School of Medicine, Tokyo, Japan.
Shinyu IzumiDepartment of Respiratory Medicine, National Center for Global Health and Medicine, Tokyo, Japan.
Machiko AritaDepartment of Respiratory Medicine, Kurashiki Central Hospital, Okayama, Japan.
Mitsuhiro AbeDepartment of Respirology, Graduate School of Medicine, Chiba University, Chiba, Japan.
Hiroyoshi YamauchiDivision of Pulmonary Medicine, Department of Medicine, Jichi Medical University, Tochigi, Japan.
Joe ShindohDepartment of Respiratory Medicine, Ogaki Municipal Hospital, Gifu, Japan.
Takafumi SudaSecond Division, Department of Internal Medicine, Hamamatsu University School of Medicine, Shizuoka, Japan.
Masaki OkamotoDivision of Respirology, Neurology, and Rheumatology, Department of Internal Medicine, Kurume University School of Medicine, Fukuoka, Japan.
Masahito EbinaDepartment of Respiratory Medicine, Tohoku Medical and Pharmaceutical University, Miyagi, Japan.
Yoshihito YamadaDepartment of Respiratory Medicine, Japan Railway Tokyo General Hospital, Tokyo, Japan.
Yuji TohdaDepartment of Respiratory Medicine and Allergology, Faculty of Medicine, Kindai University, Osaka, Japan.
Tetsuji KawamuraDepartment of Respiratory Medicine, National Hospital Organization Himeji Medical Center, Hyogo, Japan.
Yoshio TaguchiDepartment of Respiratory Medicine, Tenri Hospital, Nara, Japan.
Hiroshi IshiiDepartment of Respiratory Medicine, Fukuoka University Hospital, Fukuoka, Japan.
Naozumi HashimotoDepartment of Respiratory Medicine, Nagoya University Graduate School of Medicine, Aichi, Japan.
Shinji AbeDepartment of Respiratory Medicine, Tokyo Medical University Hospital, Tokyo, Japan.
Hiroyuki TaniguchiDepartment of Respiratory Medicine and Allergy, Tosei General Hospital, Aichi, Japan.
Jun TagawaAsahi-Kasei Pharma Corporation, Tokyo, Japan; and.
Koji BesshoAsahi-Kasei Pharma Corporation, Tokyo, Japan; and.
Natsuki YamamoriAsahi-Kasei Pharma Corporation, Tokyo, Japan; and.
Sakae HommaDepartment of Advanced and Integrated Interstitial Lung Diseases Research, School of Medicine, Toho University, Tokyo, Japan.
Toho University · JPAsahi Kasei (Japan) · JPTosei General Hospital · JPChiba University · JPFukuoka University Hospital · JPHamamatsu University School of Medicine · JPHimeji Medical Center · JPInternational University of Health and Welfare · JPJichi Medical University · JPJikei University School of Medicine · JPJR Tokyo General Hospital · JPKameda Medical Center · JPKanagawa Cardiovascular and Respiratory Center · JPKansai Rosai Hospital · JPKindai University · JPKobe City Medical Center General Hospital · JPKurashiki Central Hospital · JPKurume University · JPNagasaki University · JPNagoya University · JP
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
AdultAgedAged, 80 and overAnticoagulantsDouble-Blind MethodFemaleHumansIdiopathic Pulmonary FibrosisInfusions, IntravenousJapanMaleMiddle AgedPlacebo EffectRecombinant ProteinsSymptom Flare UpThrombomodulinAnticoagulantsRecombinant ProteinsThrombomodulinacute exacerbationanticoagulantsclinical trialidiopathic pulmonary fibrosisthrombomodulin
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
NCT05674994ClinicalTrials.gov
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.